On Demand 2026 Practice Management Course

You can earn up to 6.75 AMA PRA Category 1 Credit(s)TM.

Price: $45 College members, $60 non-members

This one-day program is designed for office administrators and physician alike and delivers dynamic updates on efficiently and effectively running your allergy practice. The PMP covers key allergy practice management topics, and our presenters are all experts in their field. 

Program Outline

2026 Allergy Coding Update
Optimizing the Allergy Office: Practical AI for Scheduling, Billing & Verification/ Smart Solutions for Revenue Growth and Operational Excellence
Cracking the Payer Code: Overcoming Denials, Downcoding, and Benefit Restrictions/ Let’s Make a Deal: Winning at Insurance Contract Negotiations
High-Performance Care Teams/ Help Is On the Way

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

  • Practice administrators/managers
  • Allergist-immunologists (both new and established)
  • Fellows in training
  • Nurse managers and other clinical staff responsible for practice management activities

Learning Objectives

Upon completion of this session, participants should be able to:

  • Adapt new coding procedures for allergy and immunology.
  • Identify and properly code difficult cases.
  • Access and utilize the vast resources of the College.
  • Identify practical strategies to increase revenue and improve financial performance in allergy practices.
  • Explore methods to streamline operations and reduce inefficiencies for better workflow management.
  • Identify the most common causes of insurance denials, downcoding, delays, and coverage limits affecting allergy and immunology practices, including current payer trends impacting immunotherapy services.
  • Accurately convey and apply recent updates to 95165
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary

Available credit: 
  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 Attendance
  • 6.75 CBRN
Course opens: 
11/24/2026
Course expires: 
12/31/2027
Cost:
$60.00
Rating: 
0

Alnoor A. Malick, MD, FACAAI
Gary N. Gross, MD, FACAAI
Andrew Nickels, MD, FACAAI
Jean L. Owen, MBA
Priya J. Bansal, MD, FACAAI
Sakina S. Bajowala, MD
Warner W. Carr, MD, FACAAI
Charlie F. Furr, Jr., MHA
Laura L. Pleasants
J. Allen Meadows, MD, FACAAI
J. Wesley Sublett, MD, MPH, FACAAI
Todd McGee, MBA
Marine Demirjian, MD, FACAAI
Kristina M. James, MD, FACAAI
Gary K. Soffer, MD
April M. Arseneau, MD, FACAAI
Melinda M. Rathkopf, MD, MBA, FACAAI

Available Credit

  • 6.75 AMA PRA Category 1 Credit™
  • 6.75 Attendance
  • 6.75 CBRN

Price

Cost:
$60.00
Please login or create an account to take this course.